Drug Trial Planned For Synthetic Cannabinoid COVID-19 Treatment

By Brendan Bures

This story originally appeared on The Fresh Toast

A Philadelphia cannabis firm has joined the race to create a COVID-19 cure using cannabinoidsFSD Pharma announced last week that the Food and Drug Administration (FDA) had approved the company’s application proposal to conduct clinical trials around the medicine. The treatment will use a drug called ultramicronized palmitoylethanolamid (or micro PEA) that includes synthetic molecules that mimic cannabinoids.

Micro PEA is a unique drug. It’s believed to act as an anti-inflammatory and promoted between 1969 and 1979 in former Czechoslovakia as treatment for influenza and the common cold. Clinical trials conducted at the time showed PEA was an effective prophylactic in respiratory infection, with no registered side effects. According to scientists behind the research, it could act as a quick therapeutic answer should a flu epidemic occur.

Read more from the source: GreenEntrepreneur.com

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.